FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SCHAISON PHILIPPE 		2. Issuer Name and Ticker or Trading Symbol

Allergan plc [ AGN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP, President Allergan Med
(Last)          (First)          (Middle)

CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,, COOLOCK, CO. 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/8/2016
(Street)

DUBLIN, L2 00000
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value $0.0001                  8620   (1) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $112.2                      (2) 10/31/2023   Ordinary Shares   16152     16152   D    
Stock Option (Right to buy)   $154.87                      (3) 2/21/2024   Ordinary Shares   16387     16387   D    
Stock Option (Right to buy)   $289.75                      (4) 2/20/2025   Ordinary Shares   8149     8149   D    
Stock Option (Right to buy)   $307.51                      (5) 3/17/2025   Ordinary Shares   8676     8676   D    
Performance Based Restricted Stock Unit     (6)                    (6)   (6) Ordinary Shares   9344     9344   D    

Explanation of Responses:
( 1)  Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
( 2)  Vests in four equal annual installments commencing on the first anniversary of the grant date (October 31, 2013).
( 3)  Vests in four equal annual installments commencing on the first anniversary of the grant date (February 21, 2014).
( 4)  Vests in four equal annual installments commencing on the first anniversary of the grant date (February 20, 2015).
( 5)  Vests in five equal annual installments commencing on the first anniversary of the grant date (March 17, 2015).
( 6)  Represents performance-based restricted share units ("PSUs") which will vest as to one-third of the total grant on each of December 31, 2017, 2018 and 2019, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SCHAISON PHILIPPE
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,
COOLOCK, CO.
DUBLIN, L2 00000

EVP, President Allergan Med

Signatures
/s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 6/8/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergan Charts.
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergan Charts.